URGN News & Analysis
3 articles
Market Mood
UroGen Pharma (URGN) CMO Sells 5,222 Shares for $143,000
Mark Schoenberg, CMO of UroGen Pharma Ltd. (URGN), sold 5,222 shares for approximately $143,000, as reported in a SEC Form 4 filing. Following the transaction, his direct ownership consists of 139,763 shares valued at about $3.81 million. This sale represents a 25.81% decrease in Schoenberg's direct holdings over the past year, where he has completed seven sell transactions. The shares were sold at a weighted average price of $27.30 amid a 168.23% one-year total return as of June 12, 2026.
Read More
UroGen Pharma Ltd. (URGN) Form 144 Filed on June 9
UroGen Pharma Ltd. (URGN) filed Form 144 on June 9 for potential transactions involving the sale of shares by insiders. This filing allows for the sale of shares under specific restrictions, which could influence the stock's liquidity. The current trading volume and any changes in share ownership following this filing are relevant for investor sentiment. Monitoring such regulatory filings helps investors gauge potential stock movements and insider activity.
Read More
UroGen Pharma (URGN) Q1 2026 EPS Beats Expectations by 10%
UroGen Pharma (URGN) reported its Q1 2026 earnings, exceeding EPS forecasts by 10%. The company's actual EPS was $1.10, compared to the anticipated $1.00. This performance is significant as it reflects UroGen's strong financial position and market confidence. Such earnings reports often influence investor sentiment and can lead to increased trading volumes in the stock. Analysts are closely watching URGN's future performance to gauge market trends.
Read More